Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Mission Therapeutics
Mission Therapeutics
Activities:
Manufacturing
Drug Delivery
Research & Development
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
Mission Therapeutics announces FDA approval for Phase II trial in acute kidney injury
Mission gains clearance from US FDA for Phase II trial of MTX562 after it receives official approval of its Investigational New Drug (IND) application
Research & Development
Mission paper outlines potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s
The research was the result of collaborative work between Cambridge University, Harvard Medical School and Mission Therapeutics
Finance
Mission appoints Dr Suhail Nurbhai CMO
Dr Nurbhai has more than 25 years of experience in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US
Ingredients
Mission raises $15m and expands relationship with Pfizer
The new capital will support the development of Mission's deubiquitylating enzymes (DUB) platform, as well as growth of its pipeline of DUB inhibitor programmes
Drug Delivery
Dr Nick Edmunds appointed to VP, Head of DUB Discovery
Recruitment
Mission Therapeutics strengthens clinical development team
Recruitment
Mission Therapeutics appoints Dr Bobby Soni to board
Subscribe now